Conflict of Interest Statement: Dr. Pierce is employed by NuPathe Inc.
Oral Triptans and Nausea: Treatment Considerations in Migraine
Article first published online: 30 MAY 2013
© 2013 NuPathe Inc.
Headache: The Journal of Head and Face Pain
Special Issue: Migraine and Gastrointestinal Manifestations – Treatment Challenges
Volume 53, Issue Supplement S1, pages 17–20, June 2013
How to Cite
Pierce, M. (2013), Oral Triptans and Nausea: Treatment Considerations in Migraine. Headache: The Journal of Head and Face Pain, 53: 17–20. doi: 10.1111/head.12110
- Issue published online: 30 MAY 2013
- Article first published online: 30 MAY 2013
- Manuscript Accepted: 5 MAR 2013
- 1Why triptan treatment can fail: Focus on gastrointestinal manifestations of migraine. Headache. 2013;53(Suppl. 1):11-16..
- 3Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database. Cephalalgia. 2008;28:34-40., , , , , .
- 6Maxalt/Maxalt-MLT [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.; 2011.
- 7Axert Tablets [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2011.
- 8Amerge Tablets [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012.
- 10Migraine and gastroparesis from a gastroenterologist's perspective. Headache. 2013;53(Suppl. 1):4-10..
- 11Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd ed. Cephalalgia. 2004;24(Suppl. 1):9-160.
- 14Imitrex Injection [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2010.